Prediction of diacerein inhibition activity against interleukin-1 receptors through docking method and tracing of pharmacokinetic profiles and their toxicity

Authors

  • Frengki Frengki Syiah Kuala University
  • Vivi Sofia Farmasi Universitas Ahmad Dahlan
  • Deddi Prima Putra Farmasi, Universitas Andalas
  • Fatma Sri Wahyuni Farmasi, Universitas Andalas
  • Daan Khambri Fakultas Kedokteran, Universitas Andalas
  • Henni Vanda Syiah Kuala University

DOI:

https://doi.org/10.12928/pharmaciana.v10i3.16445

Keywords:

Diacerein, osteoarthritis, IL-1, in silico

Abstract

IL-1 is one of the cytokines involved in joint diseases such as osteoarthritis. IL-1 plays a role in maintaining the balance of proteolytic proteins:MMPs and TIMPs inhibitors. Increased expression and uncontrolled IL-1 activity tend to increase the role of MMPs in degrading proteoglycans and joint tissue collagen. This study aims to reveal the interaction model of one of the osteoarthritis drugs, namely diacerein. A drug belongs to a group of disease-modifying osteoarthritis drugs (DMOADs) to suppressthe development of the disease rate, improving the structure and function of the cartilage and surrounding tissue. "In silico" digital test uses the technique of "molecular docking: used as a method of the approach using the MOE 2007.09 software application. The test material was in the form of a diacerein 3D structure and five control ligands, while the IL-1β / IL-1RI receptor template was downloaded from pdb.org (PDB ID: 1ITB). The ligand pharmacokinetic profile will also be displayed obtained through the ADMETSAR server. The docking results showed diacerein had the lowest docking score of -12.3285 kcal/mol with the strongest affinity, the best pharmacokinetic profile but more toxic. This study proves that the mechanism of diacerein inhibition of IL-1β / IL-1RI receptors is similar to dexamethasone, prednisolone,and minocycline.

References

Awaluddin, R., Muhtadi, W. K., Chabib, L., & Ikawati, Z. (2017). Molecular docking and ADMEtoxicity

studies of potential compounds of medicinal plants grown in Indonesia as an antirheumatoid

arthritis Molecular Docking and ADME-Toxicity Studies of Potential Compounds of

Medicinal Plants Grown In Indonesia as An Anti. AIP Conference Proceedings, 020033, 020033-

-020033–020039. https://doi.org/10.1063/1.4978106

Bansal, T., Jaggi, M., Khar, R. K., Institutes, B. S. A. E., Talegaonkar, S., & Sciences, D. P. (2014).

Emerging Significance of Flavonoids as P-Glycoprotein Inhibitors in Cancer Chemotherapy

Emerging Significance of Flavonoids as P-Glycoprotein Inhibitors in Cancer Chemotherapy.

Journal of Pharmacy and Pharmaceutical Sciences, 12 (1)(May), 46–78.

https://doi.org/10.18433/J3RC77

Bao, L., Hazari, S., & Mehra, S. (2012). Increased expression of P-glycoprotein and doxorubicin

chemoresistance of metastatic breast cancer is regulated by miR-298. The American Journal of

Pathology, 180(6), 2490–2503. https://doi.org/10.1016/j.ajpath.2012.02.024

Fernández-moreno, M., Rego, I., Carreira-garcia, V., Blanco, F. J., & Coruña, A. (2008). Genetics in

osteoarthritis. Current Genomics, 9(8), 542–547.

Frengki, Putra, D. P., Wahyuni, F. S., & Khambri, D. (2018). Uji in vitro dan in silico senyawa

,7,2’,5’-tetrahydroxy flavan-3-OL terhadap enzim alpha glucosidase. Jurnal Fitofarmaka

Indonesia, 5(2), 279–283.

Halim, S. A., & Jawad, M. (2015). Attempt to explore the binding mechanism of IL-1 β Inhibitors via

molecular attempt to explore the binding mechanism of IL-1β inhibitors via molecular docking

studies. Medical Chemistry, 5(10), 452–257. https://doi.org/10.4172/2161-0444.1000300

Hopade, A. R. C., Ayyad, F. J. S., & Ore, Y. V. P. (2015). Molecular docking studies of

phytocompounds from the phyllanthus species as potential chronic pain modulators. Scientia

Pharmaceutica, 83(2), 243–267. https://doi.org/10.3797/scipharm.1408-10

Jansen, G., Scheper, R. J., & Dijkmans, B. A. C. (2003). Multidrug resistance proteins in rheumatoid

arthritis , role in disease- modifying antirheumatic drug efficacy and inflammatory processes : An

overview Multidrug resistance proteins in rheumatoid arthritis , role in disease-modifying

antirheumatic drug ef. Scandinavian Journal of Rheumatology, 32(May), 325–336.

https://doi.org/10.1080/03009740310004333

Lawson, M. A., Parrott, J. M., Mccusker, R. H., Dantzer, R., Kelley, K. W., & Connor, J. C. O. (2013).

Intracerebroventricular administration of lipopolysaccharide induces indoleamine-2 , 3-. Journal

of Neuroinflammation, 10(1), 1–9. https://doi.org/10.1186/1742-2094-10-87

Malik, A., Afaq, S., El-gamal, B., Ellatif, M. A., Hassan, W. N., & Dera, A. (2019). Molecular

docking and pharmacokinetic evaluation of natural compounds as targeted inhibitors against

Crz1 protein in Rhizoctonia solani. 15(4), 277–286. https://doi.org/10.6026/97320630015277

Martel-pelletier, J., & Pelletier, J. (2010). Effects of diacerein at the molecular level in the

osteoarthritis disease process. Therapeutic Advances in Musculoskeletal Disease, 2(2), 95–104.https://doi.org/10.1177/1759720X09359104

Siddik, Z. H. (2003). Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene,

, 7265–7279.

Sofia, V., Ali, H., Rahmadian, R., & Amita, F. (2018). Ekspresi gen tissue inhibitor metalloproteinase-

pada sel sinoviosit osteoartritis grade IV setelah pemberian diacerein. Jurnal Kesehatan

Andalas, 7(1), 19–25.

Sripathy, R., Anjana, D., Somashekara, N., Krishnaraju, A., Krishanu, S., Murali, M., Verma, S. R., &

Ramchand, C. N. (2012). In Silico , in vitro and in vivo assessment of safety and antiinflammatory

activity of curcumin research and development , Laila Pharmaceuticals Pvt . Ltd .,

Chennai , Tamilnadu , India Research and Development , Laila Impex R and D Centre ,

Vijayawada ,. American Journal of Infectious Diseases, 8(1), 26–33.

Svetlana, E., John, R., Fruehauf, P., Kim, A. H., Stroup, R., & Although, I. (1998). Levels taxol of

Multidrug Breast and Doxorubicin ’ Resistance Cancer with in Vitro Expression to by Human

Correlate Resistance. Clinical Cancer Research, 4(February), 389–398.

Weber, M. A., Schiffrin, E. L., White, W. B., Mann, S., Lindholm, L. H., Kenerson, J. G., Flack, J. M.,

Carter, B. L., Pharm, D., Materson, B. J., & Ram, C. V. S. (2014). Clinical practice guidelines for

the management of hypertension in the community a statement by the american society of

hypertension and the international society of hypertension. Journal of Clinical Hypertension,

(1), 14–26. https://doi.org/10.1111/jch.12237

Downloads

Published

2020-10-28

Issue

Vol. 10 No. 3 (2020): Pharmaciana

Section

Pharmacology

License

Authors who publish with Pharmaciana agree to the following terms:

  1. Authors retain copyright and grant the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal. 
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.